Latest research on Desvenlafaxine

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.

Latest findings

Venlafaxine is metabolized in the liver through the cytochrome P450 system into three metabolites: O-desmethylVenlafaxine, N-desmethylVenlafaxine, and N, O-desmethylVenlafaxine. [source, 2009]
Desvenlafaxine was considered efficacious to treat MDD in the pooled analysis of the data using MMRM models. [source, 2009]
Although Venlafaxine is considered by some investigators to be a weak inhibitor of CYP 2D6 (43), CYP 2D6 plays an important role in the formation of O-desmethylVenlafaxine that is one of Venlafaxine's major metabolites (53). [source, 2006]